Terns reports TERN-701 Phase 1 PK data: no food effect, once-daily dosing supported

Terns Pharmaceuticals, Inc.

TERN-701 showed no clinically significant food effect at 80 mg; supports dosing with or without food.
PK linear across 20-160 mg; median half-life 8-12 hours; exposures at 80 and 160 mg met predicted efficacious levels.
Phase 1 CARDINAL trial in 2L+ CML ongoing; interim dose escalation data expected H2 2024.
No clinically meaningful changes in lab data, vital signs, or ECG across all dose levels.
Data consistent with Chinese Phase 1 study; plans to present at upcoming scientific conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.